Worel, Nina, Apperley, Jane F., Basak, Grzegorz W., Douglas, Kenneth W., Gabriel, Ian H., Geraldes, Catarina ORCID: 0000-0001-8627-6187, Huebel, Kai, Jaksic, Ozren, Koristek, Zdenek ORCID: 0000-0002-0478-854X, Lanza, Francesco, Lemoli, Roberto, Mikala, Gabor, Selleslag, Dominik, Duarte, Rafael F. and Mohty, Mohamad (2012). European data on stem cell mobilization with plerixafor in patients with nonhematologic diseases: an analysis of the European consortium of stem cell mobilization. Transfusion, 52 (11). S. 2395 - 2401. HOBOKEN: WILEY-BLACKWELL. ISSN 0041-1132

Full text not available from this repository.

Abstract

BACKGROUND: Plerixafor with granulocytecolony-stimulating factor (G-CSF) has been shown to enhance stem cell mobilization in patients with multiple myeloma and lymphoma with previous mobilization failure. In this European named patient program we report the experience in insufficiently mobilizing patients diagnosed with nonhematologic diseases. STUDY DESIGN AND METHODS: Thirty-three patients with germ cell tumor (n = 11), Ewing sarcoma (n = 6), Wiscott-Aldrich disease (n = 5), neuroblastoma (n = 4), and other nonhematologic diseases (n = 7) were included in the study. Plerixafor was limited to patients with previous or current stem cell mobilization failure and given after 4 days of G-CSF (n = 21) or after chemotherapy and G-CSF (n = 12) in patients who mobilized poorly. RESULTS: Overall, 28 (85%) patients succeeded in collecting at least 2 x 106/kg body weight (b.w.) CD34+ cells (median, 5.0 x 106/kg b.w. CD34+ cells; range, 2.0 x 106-29.5 x 106/kg b.w. CD34+ cells), and five (15%) patients collected a median of 1.5 x 106/kg b.w. CD34+ cells (range, 0.9 x 106-1.8 x 106/kg b.w. CD34+ cells). Nineteen patients proceeded to transplantation. The median dose of CD34+ cells infused was 3.3 x 106/kg b.w. (range, 2.3 x 106-6.7 x 106/kg b.w. CD34+ cells). The median numbers of days to neutrophil and platelet engraftment were 11 (range, 9-12) and 15 (range, 10-25) days, respectively. CONCLUSION: These data emphasize the role of plerixafor in combination with G-CSF or chemotherapy and G-CSF as an effective mobilization regimen with the potential of successful stem cell collection. Accordingly, plerixafor seems to be safe and effective in patients with nonhematologic diseases. Larger prospective studies are warranted to further assess its use in these patients.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Worel, NinaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Apperley, Jane F.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Basak, Grzegorz W.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Douglas, Kenneth W.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Gabriel, Ian H.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Geraldes, CatarinaUNSPECIFIEDorcid.org/0000-0001-8627-6187UNSPECIFIED
Huebel, KaiUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Jaksic, OzrenUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Koristek, ZdenekUNSPECIFIEDorcid.org/0000-0002-0478-854XUNSPECIFIED
Lanza, FrancescoUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Lemoli, RobertoUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Mikala, GaborUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Selleslag, DominikUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Duarte, Rafael F.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Mohty, MohamadUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-480748
DOI: 10.1111/j.1537-2995.2012.03603.x
Journal or Publication Title: Transfusion
Volume: 52
Number: 11
Page Range: S. 2395 - 2401
Date: 2012
Publisher: WILEY-BLACKWELL
Place of Publication: HOBOKEN
ISSN: 0041-1132
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
PREVIOUSLY FAILING MOBILIZATION; COLONY-STIMULATING FACTOR; NON-HODGKINS-LYMPHOMA; MULTIPLE-MYELOMA; G-CSF; PERIPHERAL-BLOOD; POOR MOBILIZERS; CHEMOTHERAPY; TRANSPLANTATION; STRATEGIESMultiple languages
HematologyMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/48074

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item